Allogeneic Hematopoietic Stem Cell Transplantation Activity in Inborn Errors of Immunity in Russian Federation.
Primary immunodeficiency
hematopoietic stem cell transplantation
inborn errors of immunity
transplantation activity
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
19
12
2022
accepted:
20
03
2023
medline:
21
7
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established therapy for many inborn errors of immunity (IEI). The indications for HSCT have expanded over the last decade. The study aimed to collect and analyze the data on HSCT activity in IEI in Russia. The data were collected from the Russian Primary Immunodeficiency Registry and complemented with information from five Russian pediatric transplant centers. Patients diagnosed with IEI by the age of 18 years and who received allogeneic HSCT by the end of 2020 were included. From 1997 to 2020, 454 patients with IEI received 514 allogeneic HSCT. The median number of HSCTs per year has risen from 3 in 1997-2009 to 60 in 2015-2020. The most common groups of IEI were immunodeficiency affecting cellular and humoral immunity (26%), combined immunodeficiency with associated/syndromic features (28%), phagocyte defects (21%), and diseases of immune dysregulation (17%). The distribution of IEI diagnosis has changed: before 2012, the majority (65%) had severe combined immunodeficiency (SCID) and hemophagocytic lymphohistiocytosis (HLH), and after 2012, only 24% had SCID and HLH. Of 513 HSCTs, 48.5% were performed from matched-unrelated, 36.5% from mismatched-related (MMRD), and 15% from matched-related donors. In 349 transplants T-cell depletion was used: 325 TCRαβ/CD19+ depletion, 39 post-transplant cyclophosphamide, and 27 other. The proportion of MMRD has risen over the recent years. The practice of HSCT in IEI has been changing in Russia. Expanding indications to HSCT and SCID newborn screening implementation may necessitate additional transplant beds for IEI in Russia.
Identifiants
pubmed: 37009957
doi: 10.1007/s10875-023-01476-w
pii: 10.1007/s10875-023-01476-w
pmc: PMC10068234
doi:
Substances chimiques
Receptors, Antigen, T-Cell, alpha-beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241-1249Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;8(7):295.
doi: 10.3389/fped.2019.00295
Barzaghi F, Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, Nademi Z, Slatter MA, Ulloa ER, Shcherbina A, Roppelt A. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study. J Allergy Clin Immunol. 2018;141(3):1036–1049.e5.
doi: 10.1016/j.jaci.2017.10.041
pubmed: 29241729
Yang L, Booth C, Speckmann C, Seidel MG, Worth AJ, Kindle G, Lankester AC, Grimbacher B, Sediva A, Neven B, Hauck F. Phenotype, genotype, treatment, and survival outcomes in patients with X-linked inhibitor of apoptosis deficiency. J Allergy Clin Immunol. 2021;150(2):456–66.
doi: 10.1016/j.jaci.2021.10.037
pubmed: 34920033
Wolska-Kusnierz B, Pastorczak A, Fendler W, Wakulinska A, Dembowska-Baginska B, Heropolitanska-Pliszka E, Piątosa B, Pietrucha B, Kałwak K, Ussowicz M, Pieczonka A. Hematopoietic stem cell transplantation positively affects the natural history of cancer in Nijmegen Breakage Syndrome. Clin Cancer Res. 2021;27(2):575–84.
doi: 10.1158/1078-0432.CCR-20-2574
pubmed: 33082212
Passweg JR, Baldomero H, Chabannon C, Basak GW, de La Cámara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester AC. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56(7):1651–64.
doi: 10.1038/s41409-021-01227-8
pubmed: 33623153
pmcid: 8263343
Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Kuball J, Lankester A, Montoto S, de Latour RP, Snowden JA. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. 2019;54(10):1575–85.
doi: 10.1038/s41409-019-0465-9
pubmed: 30728439
pmcid: 6957459
El-Helou SM, Biegner AK, Bode S, Ehl SR, Heeg M, Maccari ME, Ritterbusch H, Speckmann C, Rusch S, Scheible R, Warnatz K. The German National Registry of Primary Immunodeficiencies (2012–2017). Front Immunol. 2019;19(10):1272.
doi: 10.3389/fimmu.2019.01272
Shillitoe B, Bangs C, Guzman D, Gennery AR, Longhurst HJ, Slatter M, Edgar DM, Thomas M, Worth A, Huissoon A, Arkwright PD. The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017: the UKPID registry report: 2012-2017. Clin Exp Immunol. 2018;192(3):284–91.
doi: 10.1111/cei.13125
pubmed: 29878323
pmcid: 5980391
Mukhina AA, Kuzmenko NB, Rodina YA, Kondratenko IV, Bologov AA, Latysheva TV, Prodeus AP, Pampura AN, Balashov DN, Ilyina NI, Latysheva EA. Primary immunodeficiencies in Russia: data from the National Registry. Front Immunol. 2020;6(11):1491.
doi: 10.3389/fimmu.2020.01491
European Society for Immunodeficiencies. ESID Registry–working definitions for clinical diagnosis of PID. https://esid.org/Working-Parties/Registry-Working-Party/Diagnosis-criteria . Accessed 21 May 2022.
Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, Klein C, Morio T, Oksenhendler E, Picard C, Puel A. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507.
doi: 10.1007/s10875-022-01289-3
pubmed: 35748970
pmcid: 9244088
Dvorak CC, Haddad E, Heimall J, Dunn E, Buckley RH, Kohn DB, et al. The diagnosis of severe combined immunodeficiency (SCID): the Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 definitions. J Allergy Clin Immunol. 2022;151(2):547–55.
doi: 10.1016/j.jaci.2022.10.021
pubmed: 36456360
Laberko A, Sultanova E, Gutovskaya E, Shipitsina I, Shelikhova L, Kurnikova E, Muzalevskii Y, Kazachenok A, Pershin D, Voronin K, Shcherbina A. Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficiencies. Blood. 2019;134(20):1755–63.
doi: 10.1182/blood.2019001757
pubmed: 31558465
pmcid: 6856988
Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, Amrolia PJ, Gaspar HB, Davies EG, Friedrich W, Hoenig M. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602–610.e11.
doi: 10.1016/j.jaci.2010.06.015
pubmed: 20673987
Chiesa R, Wang J, Blok HJ, Hazelaar S, Neven B, Moshous D, Schulz A, Hoenig M, Hauck F, Al Seraihy A, Gozdzik J. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136(10):1201–11.
doi: 10.1182/blood.2020005590
pubmed: 32614953
Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, Aleinikova OV. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood. 2022;139(13):2066–79.
doi: 10.1182/blood.2021014687
pubmed: 35100336
Dimitrova D, Nademi Z, Maccari ME, Ehl S, Uzel G, Tomoda T, Okano T, Imai K, Carpenter B, Ip W, Rao K. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022;149(1):410–421.e7.
doi: 10.1016/j.jaci.2021.04.036
pubmed: 34033842
Tesch VK, Abolhassani H, Shadur B, Zobel J, Mareika Y, Sharapova S, Karakoc-Aydiner E, Riviere JG, Garcia-Prat M, Moes N, Haerynck F. Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. J Allergy Clin Immunol. 2020;145(5):1452–63.
doi: 10.1016/j.jaci.2019.12.896
pubmed: 31887391
Laberko A, Deordieva E, Krivan G, Goda V, Bhar S, Kawahara Y, Rao K, Worth A, McDermott DH, Balashov D, Maschan A. Multicenter experience of hematopoietic stem cell transplantation in WHIM syndrome. J Clin Immunol. 2022;42(1):171–82.
doi: 10.1007/s10875-021-01155-8
pubmed: 34697698
Raj R, Aboobacker FN, Yadav SP, Uppuluri R, Bhat S, Choudhry D, Dua V, Kharya G, Rastogi N, Sachdev M, Khandelwal V. Multicenter outcome of hematopoietic stem cell transplantation for primary immune deficiency disorders in India. Front Immunol. 2021;8(11):606930.
doi: 10.3389/fimmu.2020.606930
Olaya M, Franco A, Chaparro M, Estupiñan M, Aristizabal D, Builes-Restrepo N, Franco JL, Zea-Vera AF, Estacio M, Manzi E. Beltran E Hematopoietic stem cell transplantation in children with inborn errors of immunity: a multi-center experience in Colombia. J Clin Immunol. 2020;40(8):1116–23.
doi: 10.1007/s10875-020-00856-w
pubmed: 32880086
Fernandes JF, Nichele S, Daudt LE, Tavares RB, Seber A, Kerbauy FR, Koliski A, Loth G, Vieira AK, Darrigo-Junior LG, Rocha V. Transplantation of hematopoietic stem cells for primary immunodeficiencies in Brazil: challenges in treating rare diseases in developing countries. J Clin Immunol. 2018;38(8):917–26.
doi: 10.1007/s10875-018-0564-1
pubmed: 30470982
Miyamoto S, Umeda K, Kurata M, Nishimura A, Yanagimachi M, Ishimura M, Sato M, Shigemura T, Kato M, Sasahara Y, Iguchi A. Hematopoietic cell transplantation for severe combined immunodeficiency patients: a Japanese retrospective study. J Clin Immunol. 2021;41(8):1865–77.
doi: 10.1007/s10875-021-01112-5
pubmed: 34448087
pmcid: 8390179
Miyamoto S, Umeda K, Kurata M, Yanagimachi M, Iguchi A, Sasahara Y, Okada K, Koike T, Tanoshima R, Ishimura M, Yamada M. Hematopoietic cell transplantation for inborn errors of immunity other than severe combined immunodeficiency in Japan: retrospective analysis for 1985–2016. J Clin Immunol. 2022;42(3):529–45.
doi: 10.1007/s10875-021-01199-w
pubmed: 34981329
Laberko A, Yukhacheva D, Rodina Y, Abramov D, Konovalov D, Radygina S, Shelikhova L, Pershin D, Kadnikova O, Maschan M, Maschan A. BCG-Related inflammatory syndromes in severe combined immunodeficiency after TCRαβ+/CD19+ depleted HSCT. J Clin Immunol. 2020;40(4):625–36.
doi: 10.1007/s10875-020-00774-x
pubmed: 32377975
Laberko AL, Rodina YA, Deripapa EV, Roppelt AA, Yukhacheva DV, Pershin DE, Solopova GG, Brilliantova VV, Alexenko MY, Zakharova VV, Balashov DN. Influence of clinical and immunophenotypic variants of severe combined immunodeficiency on severity and outcomes of opportunistic infections. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2021;19(4):30–8.
doi: 10.24287/1726-1708-2020-19-4suppl-30-38
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, Baker M, Ballow M, Bartoshesky LE, Bonagura VR, Bonilla FA. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729.
doi: 10.1001/jama.2014.9132
pubmed: 25138334
pmcid: 4492158
Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Peffault de Latour R. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant. 2020;55(8):1604–13.
doi: 10.1038/s41409-020-0826-4
pubmed: 32066864
pmcid: 7391287
Jonkman-Berk BM, Van den Berg JM, Ten Berge IJ, Bredius RG, Driessen GJ, Dalm VA, Van Dissel JT, van Deuren M, Ellerbroek PM, van der Flier M, van Hagen PM. Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy. Clinical Immunology. 2015;156(2):154–62.
doi: 10.1016/j.clim.2014.10.003
pubmed: 25451158
Albert MH, Sirait T, Eikema DJ, Bakunina K, Wehr C, Suarez F, Fox ML, Mahlaoui N, Gennery AR, Lankester AC, Beier R. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. 2022;140(14):1635–49.
doi: 10.1182/blood.2022015506
pubmed: 35344580
Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, Rao K, Lucchini G, Silva JM, Worth A, Barge D. T-cell receptor αβ+ and CD19+ cell–depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141(4):1417–1426.e1.
doi: 10.1016/j.jaci.2017.07.008
pubmed: 28780238
Kurzay M, Hauck F, Schmid I, Wiebking V, Eichinger A, Jung E, Boekstegers A, Feuchtinger T, Klein C, Albert MH. T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors. Haematologica. 2019;104(10):e478.
doi: 10.3324/haematol.2018.215285
pubmed: 30846493
pmcid: 6886426
Neven B, Diana JS, Castelle M, Magnani A, Rosain J, Touzot F, Moreira B, Fremond ML, Briand C, Bendavid M, Levy R. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biology of Blood and Marrow Transplantation. 2019;25(7):1363–73.
doi: 10.1016/j.bbmt.2019.03.009
pubmed: 30876929
Laberko A, Sultanova E, Idarmacheva A, Skvortsova Y, Shelikhova L, Nechesnyuk A, Kobyzeva D, Shcherbina A, Maschan M, Maschan A, Balashov D. Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity. Bone Marrow Transplant. 2023;58(3):273–81. https://doi.org/10.1038/s41409-022-01883-4 .
doi: 10.1038/s41409-022-01883-4
pubmed: 36456809